Abstract
Effective systemic treatment of pancreatic cancer remains a major challenge, with progress hampered by drug resistance and treatment related toxicities. Currently available cytotoxic agents as monotherapy or in combination have provided only a modest survival benefit for patients with advanced disease. Disappointing phase III results with gemcitabine-based combinations in patients with advanced pancreatic cancer might be related to poor efficacy of systemic therapies in unselected patients. Future research strategies should prioritize identification of predictive markers through pharmacogenetic investigations. The individualization of patient treatment through pharmacogenetics may help to improve outcome by maximizing efficacy whilst lowering toxicity. This review provides an update on the pharmacogenetics of pancreatic cancer treatment and its influence on treatment benefits and toxicity.
Keywords: Pancreatic cancer, pharmacogenetics, chemotherapy, therapy, resistance, Gemcitabine, Intra-Tumoral Molecular Determinants, Clinical Outcome, Multi-drug resistant genes, focal adhesion kinase
Current Drug Targets
Title:Systemic Therapies for Pancreatic Cancer - The Role of Pharmacogenetics
Volume: 13 Issue: 6
Author(s): Ross A. Soo, Wei-Peng Yong and Federico Innocenti
Affiliation:
Keywords: Pancreatic cancer, pharmacogenetics, chemotherapy, therapy, resistance, Gemcitabine, Intra-Tumoral Molecular Determinants, Clinical Outcome, Multi-drug resistant genes, focal adhesion kinase
Abstract: Effective systemic treatment of pancreatic cancer remains a major challenge, with progress hampered by drug resistance and treatment related toxicities. Currently available cytotoxic agents as monotherapy or in combination have provided only a modest survival benefit for patients with advanced disease. Disappointing phase III results with gemcitabine-based combinations in patients with advanced pancreatic cancer might be related to poor efficacy of systemic therapies in unselected patients. Future research strategies should prioritize identification of predictive markers through pharmacogenetic investigations. The individualization of patient treatment through pharmacogenetics may help to improve outcome by maximizing efficacy whilst lowering toxicity. This review provides an update on the pharmacogenetics of pancreatic cancer treatment and its influence on treatment benefits and toxicity.
Export Options
About this article
Cite this article as:
A. Soo Ross, Yong Wei-Peng and Innocenti Federico, Systemic Therapies for Pancreatic Cancer - The Role of Pharmacogenetics, Current Drug Targets 2012; 13 (6) . https://dx.doi.org/10.2174/138945012800564068
DOI https://dx.doi.org/10.2174/138945012800564068 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Male Pelvic Pain: Beyond Urology and Chronic Prostatitis
Current Rheumatology Reviews PPARγ and Its Ligands: Potential Antitumor Agents in the Digestive System
Current Stem Cell Research & Therapy Medical Applications of Collagen and Collagen-Based Materials
Current Medicinal Chemistry Tumour-Specific Uptake of Anti-Cancer Drugs: The Future is Here
Current Drug Metabolism TGF-β1 Signalling, Connecting Aberrant Inflammation and Colorectal Tumorigenesis
Current Pharmaceutical Design Autophagy: Molecular Mechanisms and their Implications for Anticancer Therapies
Current Cancer Drug Targets Adenoviral Vectors for Cancer Gene Therapy
Current Genomics Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Biosensor Detection of COVID-19 in Lung Cancer: Hedgehog and Mucin Signaling Insights
Current Pharmaceutical Design Vitamins for Cancer Prevention and Treatment: An Insight
Current Molecular Medicine Advanced Protein Drugs and Formulations
Current Protein & Peptide Science Anti-Angiogenic Agents in Pancreatic Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Micro Arrays and Biochips: Applications and Potential in Genomics and Proteomics
Current Genomics Proteomics of Human Pulmonary Surfactant Proteins
Current Proteomics Antitumor Effects of Celastrol and Semi-Synthetic Derivatives
Mini-Reviews in Organic Chemistry Proteomics and Epigenetic Mechanisms in Stem Cells
Current Proteomics Bioactive Compounds in Some Culinary Aromatic Herbs and Their Effects on Human Health
Mini-Reviews in Medicinal Chemistry Gene Transfer and Drug Delivery with Electric Pulse Generators
Current Drug Metabolism Targeted Multifunctional Lipid-Based Nanocarriers for Image-Guided Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Antioxidant Nanoplatforms for Dermal Delivery: Melatonin
Current Drug Metabolism